Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer

Motivation: Novel approaches are needed for discovery of targeted therapies for non-small-cell lung cancer (NSCLC) that are specific to certain patients. Whole genome RNAi screening of lung cancer cell lines provides an ideal source for determining candidate drug targets. Results: Unsupervised learning algorithms uncovered patterns of differential vulnerability across lung cancer cell lines to loss of functionally related genes. Such genetic vulnerabilities represent candidate targets for therapy and are found to be involved in splicing, translation and protein folding. In particular, many NSCLC cell lines were especially sensitive to the loss of components of the LSm2-8 protein complex or the CCT/TRiC chaperonin. Different vulnerabilities were also found for different cell line subgroups. Furthermore, the predicted vulnerability of a single adenocarcinoma cell line to loss of the Wnt pathway was experimentally validated with screening of small-molecule Wnt inhibitors against an extensive cell line panel. Availability and implementation: The clustering algorithm is implemented in Python and is freely available at https://bitbucket.org/youngjh/nsclc_paper. Contact: marcotte@icmb.utexas.edu or jon.young@utexas.edu Supplementary information: Supplementary data are available at Bioinformatics online.

[1]  Mathukumalli Vidyasagar,et al.  siMacro: A Fast and Easy Data Processing Tool for Cell-Based Genomewide siRNA Screens , 2013, Genomics & informatics.

[2]  J. Mesirov,et al.  Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer , 2011, Proceedings of the National Academy of Sciences.

[3]  S. Soignet,et al.  United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[5]  M. Carmo-Fonseca,et al.  The emerging role of splicing factors in cancer , 2008, EMBO reports.

[6]  R. Pincheira,et al.  Identification of a 170-kDa protein over-expressed in lung cancers , 2001, British Journal of Cancer.

[7]  Wei Tang,et al.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.

[8]  Hans-Werner Mewes,et al.  CORUM: the comprehensive resource of mammalian protein complexes , 2007, Nucleic Acids Res..

[9]  G. Goss,et al.  Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Wiemer,et al.  The spliceosome as target for anticancer treatment , 2008, British Journal of Cancer.

[11]  Jill P. Mesirov,et al.  Cancer Vulnerabilities Unveiled by Genomic Loss , 2012, Cell.

[12]  P. Bunn,et al.  Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. , 2012, Cancer research.

[13]  A. Nobel,et al.  Finding large average submatrices in high dimensional data , 2009, 0905.1682.

[14]  A. D’Andrea,et al.  Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer , 2013, PloS one.

[15]  Haizhou Wang,et al.  Ckmeans.1d.dp: Optimal k-means Clustering in One Dimension by Dynamic Programming , 2011, R J..

[16]  C. Moskaluk,et al.  Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  B. Hemmings,et al.  Translation regulation as a therapeutic target in cancer. , 2012, Cancer research.

[18]  Andrei L. Turinsky,et al.  A Census of Human Soluble Protein Complexes , 2012, Cell.

[19]  Michael Peyton,et al.  Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer , 2013, Cell.

[20]  J. Pignon,et al.  Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. , 2012, Lung cancer.

[21]  Ellen T. Gelfand,et al.  Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies , 2014, Scientific Data.

[22]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[23]  Haiquan Chen,et al.  Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction , 2009, Journal of experimental & clinical cancer research : CR.

[24]  W. Park,et al.  Arsenic trioxide induces human pulmonary fibroblast cell death via the regulation of Bcl-2 family and caspase-8 , 2011, Molecular Biology Reports.

[25]  Nevan J. Krogan,et al.  All or Nothing: Protein Complexes Flip Essentiality between Distantly Related Eukaryotes , 2013, Genome biology and evolution.

[26]  Daniel S. Yuan,et al.  Trivalent Arsenic Inhibits the Functions of Chaperonin Complex , 2010, Genetics.

[27]  J. Hershey,et al.  Individual Overexpression of Five Subunits of Human Translation Initiation Factor eIF3 Promotes Malignant Transformation of Immortal Fibroblast Cells* , 2007, Journal of Biological Chemistry.

[28]  J. Valcárcel,et al.  The spliceosome as a target of novel antitumour drugs , 2012, Nature Reviews Drug Discovery.

[29]  D. Gandara,et al.  Incorporating Bortezomib into the Treatment of Lung Cancer , 2007, Clinical Cancer Research.

[30]  M. Moore,et al.  Meayamycin inhibits pre–messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells , 2009, Molecular Cancer Therapeutics.

[31]  John C Hunter,et al.  In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C , 2014, Proceedings of the National Academy of Sciences.

[32]  P. Pandolfi,et al.  Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. , 1998, The New England journal of medicine.

[33]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[34]  R. Perez-soler,et al.  Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[36]  John D. Storey A direct approach to false discovery rates , 2002 .

[37]  Sergei Vassilvitskii,et al.  k-means++: the advantages of careful seeding , 2007, SODA '07.

[38]  J. Engelman,et al.  ALK in lung cancer: past, present, and future. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[40]  H. Overkleeft,et al.  Proteasome inhibitors: an expanding army attacking a unique target. , 2012, Chemistry & biology.